Table 2.
Changes in BCVA, CFT, SRF height, and MD during the 6-month follow-up period after SRT.
| Baseline | 1 Month | 2 Months | 3 Months | 4 Months | 6 Months | |
|---|---|---|---|---|---|---|
| BCVA (logMAR) | ||||||
| Mean | 0.34 | 0.33 | 0.31 | 0.26 | 0.25 | 0.24 |
| SD | 0.31 | 0.3 | 0.31 | 0.24 | 0.21 | 0.24 |
| p value | 0.499 | 0.177 | 0.026 * | 0.007 * | 0.009 * | |
| CFT (μm) | ||||||
| Mean | 309.31 | 257.79 | 244.62 | 239.41 | 234.38 | 211.07 |
| SD | 81.6 | 96.8 | 86.44 | 78.11 | 81.55 | 50.21 |
| p value | 0.003 * | <0.001 * | <0.001 * | <0.001 * | <0.001 * | |
| SRF height (μm) | ||||||
| Mean | 138.36 | 85.93 | 63.5 | 64.11 | 51.68 | 23.75 |
| SD | 56.78 | 88.22 | 85.18 | 79.57 | 85.26 | 61.19 |
| p value | 0.002 * | <0.001 * | <0.001 * | <0.001 * | <0.001 * | |
| MD (dB) | ||||||
| Mean | −1.56 | −1.20 | −1.03 | |||
| SD | 1.47 | 2.86 | 2.43 | |||
| p value | 0.374 | 0.07 |
BCVA, best-corrected visual acuity; CFT, central foveal thickness; SRF, subretinal fluid; MD, mean deviation; SRT, selective retinal therapy; SD, standard deviation. * p < 0.05.